ArticleCrohn's & colitis 3602026

Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.

Stefan Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.